Canton Strategic Holdings Inc(CNTN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.45 | Insider Own | 10.75% | Shs Outstand | 77.3M | Perf Week | 5.7% |
| Market Cap | 0.16B | Forward P/E | - | EPS next Y | - | Insider Trans | -1.16% | Shs Float | 71.1M | Perf Month | -14.29% |
| Enterprise Value | 0.13B | PEG | - | EPS next Q | - | Inst Own | 28.2% | Short Float | 11.29% | Perf Quarter | 10.27% |
| Income | -0.10B | P/S | 108.37 | EPS this Y | - | Inst Trans | 17.14% | Short Ratio | 10.47 | Perf Half Y | -34.62% |
| Sales | 0.00B | P/B | 0.35 | EPS next 5Y | - | ROA | -34.14% | Short Interest | 8.03M | Perf YTD | -32.67% |
| Book/sh | 5.89 | P/C | 4.36 | EPS past 3/5Y | 84.14% 58.22% | ROE | -42.53% | 52W High | -70.39% ($6.89) | Perf Year | -30.38% |
| Cash/sh | 0.47 | P/FCF | - | Sales past 3/5Y | - | ROIC | -21.57% | 52W Low | 22.77% ($1.66) | Perf 3Y | -96.89% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 75.98% | Gross Margin | - | Volatility(W/M) | 6.17% 6.98% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 83.54 | Sales Y/Y TTM | - | Oper. Margin | -3595.17% | ATR (14) | 0.16 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.7 | EPS Q/Q | 86.23% | Profit Margin | -6559.27% | RSI (14) | 50.86 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.7 | Sales Q/Q | - | SMA20 | 2.19% ($2) | Beta | 1.49 | Target Price | $5 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -5.18% ($2.15) | Rel Volume | 0.62 | Prev Close | $1.91 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -31.54% ($2.98) | Avg Volume(3M) | 0.77M | Price | $2.04 |
| IPO | 2022/1/12 | Option/Short | No/Yes | Trades | 1760 | Volume | 473,236 | Change | 6.81% |
💊 Canton Strategic Holdings (ticker CNTN) is a US company built on a dual-structure foundation that originated from a clinical-stage biotech business and has recently added a digital asset treasury strategy centered around Canton Coin. It operates two pillars simultaneously — a drug development pipeline and participation in a digital asset network — and, as a micro-cap stock, its share price is heavily influenced by shifts in business direction and fundraising activity.
Over the past 1 year, on the lower side
70% below its 1-year high.
Traded less than usual. That is 62% of its average volume.
CNTN has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $10,837. Peers typically go for $1,089.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -96.9%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #322 of 594 in the industry
Based on market cap of $163M.
UPB#320 Upstream Bio Inc $163M PER - 
ALXO#321 Alx Oncology Holdings Inc $163M PER - CNTN#322 Canton Strategic Holdings Inc $163M PER - 
NGEN#323 NervGen Pharma Corp $161M PER - 
PDSB#324 PDS Biotechnology Corp $160M PER - 
FAQ
What kind of company is CNTN?
CNTN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CNTN?
The market cap of CNTN is approximately $163M, ranking 4,176 within its sector.
What is the 52-week high and low for CNTN?
CNTN has recorded a 52-week high of $6.89 and a low of $1.66.
